Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ulcerative colitis
Biotech
Caldera hits Nasdaq via Synlogic reverse merger
Caldera has struck a merger with publicly traded Synlogic and inked a $278 million financing deal, continuing the meteoric rise of the IBD startup.
Nick Paul Taylor
Jul 29, 2026 8:56am
Abivax stock rebounds on colitis prospect safety data
Jun 30, 2026 10:27am
Merck anti-TL1A antibody from Prometheus buy passes ph. 3 test
Jun 22, 2026 10:17am
cAMPfield harvests $180M series A to advance oral IBD asset
Jun 18, 2026 10:34am
Spyre bolsters ulcerative colitis ambitions with ph. 2 win
Jun 15, 2026 3:19pm
Abivax stock suffers as cancer cases overshadow stellar efficacy
Jun 2, 2026 5:30am
